Metrics as of 10/15/2026, 02:17 PM (Berlin time), refresh in progress.
Lifecore Biomedical Stock
Lifecore Biomedical, Inc.
Company data
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- United States
- CEO
- Paul Josephs
- Employees
- 382
- Market cap
- $243 M
- IPO
- 15/02/1996
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of…
Lifecore Biomedical stock: price history
1D
+0.0%
1W
-0.3%
1M
+51.1%
6M
+19.3%
YTD
-21.5%
1Y
-1.8%
2Y
+38.7%
5Y
-34.6%
10Y
-53.1%
Next earnings date
Next earnings date
03/11/2026 (in 17 days)
Volatility around earnings
~293% stronger price swings than usual
Ask the agents about Lifecore Biomedical
Analyst assessment of Lifecore Biomedical
PRICE TARGET LOW
US$6.28
CONSENSUS
US$6.39
MEDIAN
US$6.39
PRICE TARGET HIGH
US$6.50
0
STRONG BUY
4
BUY
4
HOLD
0
SELL
0
STRONG SELL
8
TOTAL · Buy
As of: 29/09/2026
Lifecore Biomedical stock metrics
P/E
-5.84
P/B
14.99
EV/EBITDA
-92.1
RETURN ON EQUITY
18.1%
NET MARGIN
-18.0%
DEBT/EQUITY
-4.55
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
90.4%
FLOAT SHARES
34,260,778
AVG. DAILY VOLUME (30D)
516,883
Insider transactions (SEC)
Kiper Christopher S
OBUS NELSON
HOUDE LOVAS KATRINA
Schechter Joshua
Aryeh Jason
Institutional holders
Comparable stocks
Frequently asked questions about Lifecore Biomedical stock
What does Lifecore Biomedical do?
Lifecore Biomedical, Inc. is a company in the Healthcare sector, Drug Manufacturers - Specialty & Generic industry, headquartered in United States.
The CEO is Paul Josephs, the company employs around 382 people.
The IPO was on 15/02/1996; the stock trades on NASDAQ under the ticker LFCR.
What do analysts say about Lifecore Biomedical stock?
8 analysts rate the stock, the consensus is Buy (as of 29/09/2026).
The average price target is US$6.39, ranging from US$6.28 to US$6.50, with a median of US$6.39.
This is an external assessment, not a statement by Market Jury.
When does Lifecore Biomedical report next?
The next earnings date is 03/11/2026.
Around past earnings, price swings were roughly 293% stronger than usual.
Does Lifecore Biomedical pay a dividend?
No, Lifecore Biomedical currently does not pay a dividend.
Which stocks are comparable to Lifecore Biomedical?
Comparable stocks include Zoetis, Viatris, Lantheus Holdings, Amneal Pharmaceuticals, Indivior Pharmaceuticals, Eton Pharmaceuticals, Pacira BioSciences and Amphastar Pharmaceuticals.
How can I get Lifecore Biomedical stock analyzed?
Clicking "Analyze stock" lets five strategies assess Lifecore Biomedical against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.